COVID, flu, RSV: how these common viruses are tracking this winter – and how to protect yourself
Last week, non-urgent surgeries were paused in several Queensland hospitals due to a surge of influenza and COVID cases filling up hospital beds.
Meanwhile, more than 200 aged care facilities around Australia are reportedly facing COVID outbreaks.
So, just how bad are respiratory infections this year, and which viruses are causing the biggest problems?
COVID
Until May, COVID case numbers were about half last year's level, but June's 32,348 notifications are closing the gap (compared with 45,634 in June 2024). That said, we know far fewer people test now than they did earlier in the pandemic, so these numbers are likely to be an underestimate.
According to the latest Australian Respiratory Surveillance Report, Australia now appears to be emerging from a winter wave of COVID cases driven largely by the NB.1.8.1 subvariant, known as 'Nimbus'.
Besides classic cold-like symptoms, this Omicron offshoot can reportedly cause particularly painful sore throats as well as gastrointestinal symptoms such as nausea and diarrhoea.
While some people who catch COVID have no symptoms or just mild ones, for many people the virus can be serious. Older adults and those with chronic health issues remain at greatest risk of experiencing severe illness and dying from COVID.
Some 138 aged care residents have died from COVID since the beginning of June.
The COVID booster currently available is based on the JN.1 subvariant. Nimbus is a direct descendant of JN.1 – as is another subvariant in circulation, XFG or 'Stratus' – which means the vaccine should remain effective against current variants.
Free boosters are available to most people annually, while those aged 75 and older are advised to get one every six months.
Vaccination, as well as early treatment with antivirals, lowers the risk of severe illness and long COVID. People aged 70 and older, as well as younger people with certain risk factors, are eligible for antivirals if they test positive.
Influenza
The 2025 flu season has been unusually severe. From January to May, total case numbers were 30% higher than last year, increasing pressure on health systems.
More recent case numbers seem to be trending lower than 2024, however we don't appear to have reached the peak yet.
Flu symptoms are generally more severe than the common cold and may include high fever, chills, muscle aches, fatigue, sore throat and a runny or blocked nose.
Most people recover in under a week, but the flu can be more severe (and even fatal) in groups including older people, young children and pregnant women.
An annual vaccination is available for free to children aged 6 months to 4 years, pregnant women, those aged 65+, and other higher-risk groups.
Queensland and Western Australia provide a free flu vaccine for all people aged 6 months and older, but in other states and territories, people not eligible for a free vaccine can pay (usually A$30 or less) to receive one.
RSV
The third significant respiratory virus, respiratory syncytial virus (RSV), only became a notifiable disease in 2021 (before this doctors didn't need to record infections, meaning data is sparse).
Last year saw Australia's highest case numbers since RSV reporting began. By May, cases in 2025 were lower than 2024, but by June, they had caught up: 27,243 cases this June versus 26,596 in June 2024. However it looks as though we may have just passed the peak.
RSV's symptoms are usually mild and cold-like, but it can cause serious illness such as bronchiolitis and pneumonia. Infants, older people, and people with chronic health conditions are among those at highest risk. In young children, RSV is a leading cause of hospitalisation.
A free vaccine is now available for pregnant women, protecting infants for up to six months. A monoclonal antibody (different to a vaccine but also given as an injection) is also available for at-risk children up to age two, especially if their mothers didn't receive the RSV vaccine during pregnancy.
For older adults, two RSV vaccines (Arexvy and Abrysvo) are available, with a single dose recommended for everyone aged 75+, those over 60 at higher risk due to medical conditions, and all Aboriginal and Torres Strait Islander people aged 60+.
Unfortunately, these are not currently subsidised and cost about $300. Protection lasts at least three years.
The common cold
While viruses including COVID, RSV and influenza dominate headlines, we often overlook one of the most widespread – the common cold.
The common cold can be caused by more than 200 different viruses – mainly rhinoviruses but also some coronaviruses, adenoviruses and enteroviruses.
Typical symptoms include a runny or blocked nose, sore throat, coughing, sneezing, headache, tiredness and sometimes a mild fever.
Children get about 6–8 colds per year while adults average 2–4, and symptoms usually resolve in a week. Most recover with rest, fluids, and possibly over-the-counter medications.
Because so many different viruses cause the common cold, and because these constantly mutate, developing a vaccine has been extremely challenging. Researchers continue to explore solutions, but a universal cold vaccine remains elusive.
How do I protect myself and others?
The precautions we learned during the COVID pandemic remain valid. These are all airborne viruses which can be spread by coughing, sneezing and touching contaminated surfaces.
Practise good hygiene, teach children proper cough etiquette, wear a high-quality mask if you're at high risk, and stay home to rest if unwell.
You can now buy rapid antigen tests (called panel tests) that test for influenza (A or B), COVID and RSV. So, if you're unwell with a respiratory infection, consider testing yourself at home.
While many winter lurgies can be trivial, this is not always the case. We can all do our bit to reduce the impact.
This article is republished from The Conversation. It was written by: Adrian Esterman, University of South Australia
Read more:
Here's why 3-person embryos are a breakthrough for science – but not LGBTQ+ families
Pumped up with poison: new research shows many anabolic steroids contain toxic metals
From painkillers to antibiotics: five medicines that could harm your hearing
Adrian Esterman receives funding from the Medical Research Future Fund.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
2 minutes ago
- The Hill
Where the summer COVID-19 infections are hitting hardest
The number of people with COVID-19 in the U.S. is low but increasing, according to Centers for Disease Control and Prevention data released Friday. COVID-19 is trending up in many Mid-Atlantic, Southeast, Southern, and West Coast states. The agency said infections are 'growing or likely growing' in 40 states, based on emergency department visit data as of July 29. Infections were unchanged in nine states. The weekly percentage of emergency department visits among people diagnosed with COVID-19 is low, but growing, CDC said. Visits were highest for children younger than 4 years old, which experts said makes sense because many remain unvaccinated. WastewaterSCAN, which monitors infectious diseases through municipal wastewater systems, categorized national coronavirus levels as 'high' and trending upward since mid-July. According to CDC, the wastewater viral activity level for coronavirus is currently low, and only Alabama, Florida, Kentucky, Louisiana, California, Alaska and Texas reported 'high' or 'very high' levels. Experts say a lack of data is making it harder to track COVID-19 in real time, but the available information indicates the expected seasonal wave is happening. Ever since 2020, COVID-19 has peaked twice a year. Cases rise in the winter and drop into the spring, and then again in the summer as travel peaks and people seek air-conditioned indoor spaces away from the heat. While other respiratory viruses remain at low levels until the winter, experts have said COVID-19's ability to mutate sets it apart and contributes to a much higher baseline infection rate. More cases circulating year-round means more opportunities for the virus to mutate. The vaccine being updated for the coming fall season is targeted to the JN.1 variant, as it was last year. But Health and Human Services Secretary Robert F. Kennedy Jr. has significantly narrowed recommendations on who should get the vaccine, raising significant questions about the availability and affordability come the fall. In May, Kennedy said the shots would no longer be recommended for healthy kids, a decision that health experts have said lacks scientific basis. A coalition of medical groups subsequently sued over the move. In addition, a new policy requires all updated COVID-19 vaccines to undergo extensive placebo-controlled clinical trials, as if it were a new shot rather than an update to one that already exists. The updated Covid shots are expected to be available in the fall to adults 65 and up and kids and adults with at least one medical condition that puts them at risk for severe illness — the groups exempt from the clinical trial requirement.
Politico
3 hours ago
- Politico
Experts' bird flu warning
With David Lim, Erin Schumaker and Simon Levien Driving the Day BIRD FLU LATEST — Bird flu, for the moment, appears to be under control. But experts have a warning for federal and state health officials: Fall is coming — so don't get too comfortable, Sophie and David report. Over the past few months, avian flu cases among humans, cattle and poultry have slowed — easing fears that the U.S. could be hurdling toward another major pandemic and prompting the CDC to end its emergency response. When viruses collide: Eight public health experts and two state health officials from Washington and California — two states hit especially hard by the outbreak — told POLITICO that the decision makes sense if the federal government's case count is accurate. But they warned that things could shift quickly as the weather cools off. The seasonal migration of birds and the human flu season will increase the chance of a fall influenza-bird flu mash-up, which could make it more likely that bird flu will spread among humans, the experts warned. 'The most likely scenario is that someone will get infected with both H5N1 and a seasonal flu virus, and they will swap genes, and that reassortment could kick off the next pandemic,' said Jennifer Nuzzo, a professor of epidemiology and director of the Pandemic Center at Brown University School of Public Health. And the emergency's end comes after the Trump administration canceled hundreds of millions of dollars it had awarded to Moderna to help the company develop an mRNA vaccine for flu strains with pandemic potential — including avian flu — leading some experts worried the U.S. isn't doing enough to prepare for the possibility of an avian flu outbreak. 'We are going to see another influenza pandemic, and it could be much worse than we saw with Covid, and we're not preparing for that at all,' said Dr. Michael T. Osterholm, director of the Center for Infectious Disease Research and Policy at the University of Minnesota. 'We have an opportunity with mRNA technology to make a vaccine much faster … and yet, if you look right now, we've cut all funding within the U.S. government for that type of work.' An accurate case count? The World Health Organization, the Food and Agriculture Organization of the United Nations and the World Organisation for Animal Health recently issued a joint assessment that the global public health risk of avian flu is low. The groups said their confidence in the assessment is medium, partly because there 'may be biases in surveillance, testing and reporting.' Nuzzo cautioned that hesitation among farmworkers — many of whom are undocumented — to be tested for the virus, as well as local politics, might make it more difficult to test people who've been potentially exposed to the virus in the fall. 'A matter of time': Bird flu this summer has been comparatively quieter compared with this time last year, and Nuzzo doesn't think the virus is spreading under the radar at similar levels seen last summer. But she cautioned that while it's not clear when another flu pandemic will emerge, it's only a matter of time. Three major flu pandemics struck during the 1900s, part of a pattern of recurring outbreaks throughout history. Former CDC principal deputy director Nirav Shah said increased global connectivity, the convergence of the boundaries between animals and humans, climate change and the rise of dense cities mean the number of pandemic flus in the past century should be viewed as a baseline, even though society has new treatments and other methods to intervene faster than in the past. WELCOME TO MONDAY PULSE. The Senate adjourned Saturday evening, meaning we're officially in August recess season. Send your tips, scoops and feedback to khooper@ and sgardner@ and follow along @kelhoops and @sophie_gardnerj. AROUND THE AGENCIES BLUE STATE REBUTTAL — Blue states filed a brief Friday opposing the Trump administration's request to the Supreme Court for relief from a lower court's order, Erin reports. That order had blocked the administration from cutting grants related to diversity, equity and inclusion from the National Institutes of Health. 'The only unlawful decisions here are the federal government's,' the brief says. 'The only urgency is that manufactured by NIH in its haste to implement its unprecedented and unreasoned policies. The government has not shown any need for a stay.' In addition to being unnecessary, plaintiffs argued a stay would harm universities and institutions in their states and could hurt the public if, for example, clinical trials are canceled. Plaintiff states included Arizona, California, Colorado, Delaware, Hawaii, Maryland, Massachusetts, Minnesota, Nevada, New Jersey, New Mexico, New York, Oregon, Rhode Island, Washington, and Wisconsin. The administration requested relief last week on the grounds that the federal government shouldn't be required to pay for research not aligned with President Donald Trump's executive orders and his administration's priorities. Key context: U.S. District Judge William Young ordered the administration in June to restore hundreds of scientific grants the NIH terminated this year. During a hearing on two lawsuits about grant terminations, the Massachusetts judge, a former President Ronald Reagan appointee, rebuked the administration for what he called 'appalling' and 'palpably clear' discrimination against racial minorities and LGBTQ+ Americans. Industry Intel COMMON GROUND WITH AMA — Dr. Bobby Mukkamala, the American Medical Association's new president, is seeking common ground with Health Secretary Robert F. Kennedy Jr., even as the AMA has skirmished with Kennedy over his changes at HHS, Simon reports. Mukkamala told POLITICO on Friday he supports Kennedy's push to swap out unhealthy food additives, like Coca-Cola's decision to replace high-fructose corn syrup with cane sugar in its soda recipe. He added that he wants to prevent food producers from 'dictating' Americans' diets. Mukkamala, an otolaryngologist, has a background in lifestyle medicine, which lines up with Kennedy's interest in preventive care. But Mukkamala, who has been gearing up for his role for several months, said he hasn't met or spoken with the secretary. He earlier sent two letters to Kennedy on his personal letterhead that he described as entreaties to find common ground upon his appointment as secretary. His letters went unanswered, Mukkamala said at the Asian American Journalists Association conference in Seattle on Friday. Kennedy has been critical of the AMA, arguing it doesn't have patients' best interests in mind, as the group has pushed back and argued that the secretary has devalued expertise in HHS ranks. The doctors' group criticized the purge of experts from a vaccine safety panel and warned gravely about a similar dismissal Kennedy might take against an HHS preventative care task force. Mukkamala, in his AAJA session, was also skeptical of Susan Monarez, the first nonphysician to lead the CDC in decades after her confirmation Tuesday. 'To have someone that is a medical doctor is critically important,' he said. 'And you put them in a position like that, you have to wonder, how good are they going to be at that, right?' Monarez earned a doctorate in microbiology and immunology and was deputy director of ARPA-H, the agency former President Joe Biden created several years ago to invest in high-risk, high-reward research. Public Health NEW KENNEDY OP-ED — On Friday afternoon, HHS Secretary Robert F. Kennedy Jr. took to a publication called Trial Site News — a website that often publishes anti-vaccine activists — to criticize a recent study by Danish researchers that found no harms associated with exposure to low amounts of aluminum through early childhood vaccinations. Before Kennedy became health secretary, he spread misinformation about vaccines and co-founded the Children's Health Defense, an anti-vaccine group. The study, published in the Annals of Internal Medicine in July, used nationwide registry data of more than 1,000,000 children to look for links between aluminum exposure and 50 chronic disorders, including autism. Kennedy argues that the study's design makes its results unreliable, including the decision to exclude children diagnosed with certain congenital or preexisting conditions from the study. 'The architects of this study meticulously designed it not to find harm,' Kennedy writes. 'From the outset, Andersson et al. excluded the very children most likely to reveal injuries associated with high exposures to aluminum adjuvants in childhood vaccines.' The study's first author did not respond to a request for comment. The findings largely align with other studies that have found no evidence linking vaccines to autism or other neurological conditions. WHAT WE'RE READING POLITICO's Samuel Benson reports that West Virginia schools have banned certain artificial food dyes. CBS News' Kaia Hubbard reports on CMS Administrator Mehmet Oz announcing applications for the rural hospital fund will go out in early September.
UPI
3 hours ago
- UPI
Korean scientists say they developed oral drug against COVID-19
An illustration is intended to show how CP-COV03, or Xafty, works against COVID-19 in the body. Image courtesy of Hyundai Bioscience SEOUL, Aug. 4 (UPI) -- A group of scientists, primarily from South Korean universities, has confirmed the efficacy of an oral anti-viral treatment, called CP-COV03 or Xafty, against COVID-19 after a clinical trial. If a later-stage trial is successful and the medication is approved by the Ministry of Food and Drug Safety, the drug could be available next year. Developed by Korea's biotech company Hyundai Bioscience, the drug was found to address major COVID-19 symptoms listed by the U.S. Food and Drug Administration, including cough, headache, sore throat, nausea and chills. The findings were published in the latest edition of the peer-reviewed journal Nature Communications. "We conducted a randomized, double-blind, placebo-controlled clinical trial with 300 patients to learn that CP-COV03 was effective in improving COVID-19 symptoms for more than 48 hours, with no serious adverse events," Dankook University professor Choy Jin-ho told UPI. He is one of the paper's corresponding co-authors. "Patients treated with CP-COV03 returned to usual health more quickly and had a lower risk of hospitalization compared to the control group. This shows that the drug is safe and effective in patients suffering from mild to moderate COVID-19," he said. Choy said he expects that CP-COV03 to have strong commercial potential because it was based on niclosamide, a well-known medication previously used to treat tapeworm infections. "Niclosamide's clinical use has been limited due to poor solubility and bioavailability. However, our study indicates that niclosamide-based CP-COV03 works as a safer and more effective alternative to previous COVID-19 treatments such as Paxlovid," Choy said. Hyundai Bioscience noted that the Seoul-based company would develop CP-COV03 as a versatile anti-viral treatment for a range of diseases, beyond just COVID-19. "We are prepared to produce CP-COV03 as a broad-spectrum treatment once we are authorized to do so in our target countries," Hyundai Bioscience CEO Bae Byoung-jun said in a phone interview. "To use CP-COV03 as a treatment for dengue fever, for example, we have received approval to start a seamless phase II/III clinical trial in Vietnam. We hope to launch the study this year, with the aim of bringing the drug to market next year," he said.
